Vivus, Inc.: VVUS (NASDAQ)
Positive Results from Phase II Trial for ALISTA(TM)
for Female Sexual Dysfunction to Be Presented at
2002 Annual Meeting of the American Urological Association
First Data Demonstrating Drug Can Improve Sexual
Arousal and Satisfaction in Women
MOUNTAIN VIEW, Calif.--May 22, 2002--VIVUS, Inc. (Nasdaq:VVUS),
will present detailed data from its Phase II clinical trial of
ALISTA(TM), its proprietary topical formulation of alprostadil for the
treatment of Female Sexual Arousal Disorder (FSAD), at the Annual
Meeting of the American Urological Association on Monday, May 27 at
10:00 am Eastern Time.
Dr. Marc Gittelman, Co-Director of Uro-Medix P.A./Uro-Care P.A.
and Medical Director of South Florida Medical Research, will present
the data in a poster entitled, "In-Clinic Evaluation of the Safety and
Efficacy of Topical Alprostadil (PGE1) for the Treatment of Female
Sexual Dysfunction."
This is the first well-controlled Phase II in-clinic study to
demonstrate that a topically applied medication can improve sexual
arousal and satisfaction in post-menopausal women with FSAD.
The study was a double-blind, placebo-controlled, crossover-design
trial that evaluated patient responses to ALISTA administered in the
clinic in conjunction with visual sexual stimulation. A total of 79
patients with a primary complaint of FSAD were treated at six
investigational sites.
VIVUS, Inc. is a pharmaceutical company engaged in the development
of innovative therapies for the treatment of quality-of-life disorders
in men and women, with a focus on sexual dysfunction. Current
development programs target Female Sexual Dysfunction (FSD), Erectile
Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two
innovations in the treatment of erectile dysfunction, and has
partnered with Abbott Laboratories (NYSE:ABT) for the international
marketing and distribution of its male transurethral ED products. In
Canada, VIVUS has partnered exclusively with Paladin Labs (TSE:PLB) to
market and distribute MUSE.
This news release contains forward-looking statements about the
potential commercialization of products in treating female sexual
dysfunction and reflects management's current beliefs. However, as
with any pharmaceutical under development, there are significant risks
in development, regulatory approval and commercialization of new
products. There are no guarantees that any product will receive
regulatory approval for any indication. Further, even if the Company
were to receive regulatory approval for a product, there could be no
assurance that such a product would prove to be commercially
successful. Please see the Company's filings with the Securities and
Exchange Commission including, without limitation, the Company's Form
10-K and Forms 10-Q, which identify these and other risks and
uncertainties that may cause actual results or events to differ
materially from those described in this news release.
--30--
CONTACT: VIVUS, Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates, Inc. (Investor Contacts)
Bruce Voss / Jody Cain, 310/691-7100
bvoss@lhai.com / jcain@lhai.com
or
The Investor Relations Group (Media Contact)
Lisa Lindberg, 212/825-3210
theproteam@aol.com |
